Top 2 Consumer Stocks That May Implode This Month

BenzingaApr 23 21:16

Olin Bio: The recombinant golden staph vaccine is expected to be mass-produced in 2027. There is still considerable market space for the adsorbed tetanus vaccine | Directly focus on the Shareholder meeting.

① From Olin's 2024 annual performance, both revenue and net income attributable to the parent company have achieved year-on-year growth. The annual sales revenue of the adsorbed tetanus vaccine has exceeded 0.5 billion yuan for the first time; ② A relevant person in charge of the company stated that among the four major "super bacteria" vaccines currently being researched, the recombinant Staphylococcus aureus vaccine will complete the clinical phase III enrollment and is expected to achieve mass production by 2027.

cls.cnApr 23 09:58

Cadre Holdings Declares $0.095 Dividend

Seeking AlphaApr 23 04:30

Supreme Court Declines To Hear Minnesota's Appeal Defending State's Age Minimum Of 21 To Carry Handguns In Public

BenzingaApr 21 21:32

AMMO Marks Strategic Shift With Asset Name, Streamlined Operations, and Name Change

Seeking AlphaApr 21 18:37

What's Going On With Plug Power Stock On Thursday?

BenzingaApr 18 03:05